(Q38217355)

31 August 2017

1 reference

title

Cyclosporine in dermatology. (English)

1 reference

31 August 2017

1 reference

Gupta AK

1

1 reference

31 August 2017

Brown MD

2

1 reference

31 August 2017

Ellis CN

3

1 reference

31 August 2017

Rocher LL

4

1 reference

31 August 2017

Fisher GJ

5

1 reference

31 August 2017

Baadsgaard O

6

1 reference

31 August 2017

Cooper KD

7

1 reference

31 August 2017

Voorhees JJ

8

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

Journal of the American Academy of Dermatology

31 August 2017

published in

1 reference

31 August 2017

volume

21

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

1245-1256

1 reference

Immunopharmacological monitoring of cyclosporin A-treated recipients of cadaveric kidney allografts

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Clinical pharmacokinetics of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Intravenous cyclosporine kinetics in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine drug interactions: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Action and toxicity of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

The effects of cyclosporin A on the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

T-cell subpopulations in the blood and skin of patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine: a new immunosuppressive agent for organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclophilin: a specific cytosolic binding protein for cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin and psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Short-term use of cyclosporin A in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

1 reference

7 January 2021

Cyclosporin A treatment of severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Clearance of psoriasis with low dose cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of resistant severe psoriasis with systemic cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Low-dose cyclosporin A in severe psoriasis. A double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in the treatment of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Ciclosporin A in acrodermatitis continua

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

In situ demonstration of T cells in alopecia areata

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Placebo-controlled trial of topical cyclosporin in severe alopecia areata.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Topical cyclosporin in alopecia areata and nickel contact dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin-A-induced hair growth in human renal allograft recipients and alopecia areata

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine and male-pattern alopecia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Topical cyclosporin and psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Improvement of ichthyosis by cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in lamellar ichthyosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Effects of cyclosporin on bullous pemphigoid and pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of nine cases of pemphigus vulgaris with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of intraocular inflammatory disease with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Effectiveness of cyclosporin therapy for Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A is effective, but not safe, in the management of Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of epidermolysis bullosa acquisita with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine A in epidermolysis bullosa acquisita

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Clearing of epidermolysis bullosa acquisita with cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of Sézary syndrome with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of cutaneous T cell lymphoma with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Remission in skin infiltrate of a patient with mycosis fungoides treated with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A therapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin a (cyclosporine) in the treatment of cutaneous T cell lymphoma (mycosis fungoides)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with ciclosporin A: a word of caution

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine for juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin for polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin for polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Severe dermatomyositis treated with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin for acute dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in the treatment of intractable polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine treatment for intractable polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in the treatment of lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporine in successful control of rapidly progressive scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Pyoderma gangrenosum treated with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Pyoderma gangrenosum. Response to cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Treatment of recalcitrant pyoderma gangrenosum with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin for pulmonary sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Side effects of systemic cyclosporine in patients not undergoing transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Hyperkalaemia in cyclosporin-treated renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cancers following cyclosporine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Complications of cyclosporin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A hepatotoxicity in 66 renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Cyclosporin A treatment of refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Light and electron microscopic study of cyclosporin A-induced gingival hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Changes in facial appearance during cyclosporin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Hypertrichosis in patients receiving cyclosporine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

The presence of cyclosporine in body tissues and fluids during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Anaphylactic reaction to intravenous cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Absence of allergic reaction to cyclosporin capsules in patient allergic to standard oral and intravenous solution of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Topical cyclosporine in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

Intralesional injection of cyclosporin in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2889%2970339-X

7 January 2021

10.1016/S0190-9622(89)70339-X

Identifiers

DOI

1 reference

31 August 2017

1 reference